X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines

By Nicole Longo  |    December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...   Read More

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

By Tom Wilbur  |    November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...   Read More

What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation

By Tom Wilbur  |    October 31, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be the wrong approach for patients, the U.S. health care system and the economy.   Read More

Pelosi’s radical plan leaves lung cancer patients behind

By Tom Wilbur  |    October 23, 2019
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new...   Read More

Pelosi’s radical plan would leave Alzheimer’s patients behind

By Tom Wilbur  |    October 16, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...   Read More

Event tomorrow: Maintaining America’s leadership in access and innovation

By Andrew Powaleny  |    October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...   Read More

What they are saying: Broad opposition to Pelosi’s radical drug pricing plan

By Tom Wilbur  |    October 10, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be the wrong approach for patients, the U.S. health care system, economy, and American innovation. An...   Read More

On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions

By Megan Van Etten  |    October 4, 2019
Each year, the first Friday in October marks Manufacturing Day, an annual recognition of the critical role manufacturing-intensive industries play in powering innovation and generating jobs and...   Read More

By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk

By Tom Wilbur  |    September 26, 2019
We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is the wrong approach for patients, the U.S. health care system, and American innovation. But...   Read More

World Trade Month: How we can expand world-class pro-innovation standards

By Douglas Petersen  |    May 22, 2019
May is World Trade Month—a celebration of the industries that import and export goods and services around the world. The month offers a good opportunity to examine the significance of...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates